Table 4.
Adverse events associated with trabectedin treatment.
| Adverse event, n (%) | Hematological toxicity |
||
|---|---|---|---|
| Overall | Grade 1/2 | Grade 3/4 | |
| Neutropenia | 11 (30.5) | 4 (11.1) | 7 (19.4) |
| Anemia | 9 (25.0) | 7 (19.4) | 2 (5.6) |
| Febrile neutropenia | 2 (5.6) | 0 (0.0) | 2 (5.6) |
| Thrombocytopenia | 1 (2.7) | 0 (0.0) | 1 (2.7) |
| Non-hematological toxicity | |||
| Fatigue | 9 (25.0) | 8 (22.2) | 1 (2.7) |
| Nausea | 5 (13.9) | 5 (13.9) | 0 (0.0) |
| Vomiting | 4 (11.1) | 4 (11.1) | 0 (0.0) |
| Diarrhea | 2 (5.6) | 2 (5.6) | 0 (0.0) |
| Decreased appetite | 2 (5.6) | 2 (5.6) | 0 (0.0) |
| Elevation in ALT | 2 (5.6) | 2 (5.6) | 0 (0.0) |
| Elevation in AST | 1 (2.7) | 1 (2.7) | 1 (2.7) |
| Constipation | 1 (2.7) | 1 (2.7) | 0 (0.0) |
| Myalgia | 1 (2.7) | 1 (2.7) | 0 (0.0) |
| Hypotension | 1 (2.7) | 1 (2.7) | 0 (0.0) |
| Hypocalcemia | 1 (2.7) | 1 (2.7) | 0 (0.0) |
| Mucositis | 1 (2.7) | 1 (2.7) | 0 (0.0) |
| Infection | 1 (2.7) | 0 (0.0) | 1 (2.7) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase.